Posted On: 02/21/2015 1:21:51 PM
Post# of 30074
Zoom: We did our license agreement with Urano in December of 2013.
In June of 2014 recombinant MANF was Urano's main focus.
However, by September of 2014 he said he "preferred" the small molecule method instead of recombinant MANF.
Then on February 17, 2015 (Last week) Urano indicated he is still pursuing the small molecule method of targeting MANF in the body through receptors.
So, while treating wolframs/diabetes with recombinant MANF is not dead, it is not our guy Urano's primary focus!
Recombinant MANF is what Urano prefers for treating Eye damage caused by wolframs/diabetes.
I can't say it any clearer for you, pal.
In June of 2014 recombinant MANF was Urano's main focus.
However, by September of 2014 he said he "preferred" the small molecule method instead of recombinant MANF.
Then on February 17, 2015 (Last week) Urano indicated he is still pursuing the small molecule method of targeting MANF in the body through receptors.
So, while treating wolframs/diabetes with recombinant MANF is not dead, it is not our guy Urano's primary focus!
Recombinant MANF is what Urano prefers for treating Eye damage caused by wolframs/diabetes.
I can't say it any clearer for you, pal.
(0)
(0)
